Skip to content

Biote Corp. BTMD Additional Paid-In Capital

Additional Paid-In Capital at other companies

Target logo
TargetTGT
$7.22B+3.0%
Walmart
 logo
Walmart WMT
$6.9B+26.8%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
$209.71M+1.5%
BioLife Solutions logo
BioLife SolutionsBLFS
$710.81M+3.3%
NAG
Niagen Bioscience, Inc. Common StockNAGE
$240.46M+3.6%
Lifevantage Corporation logo
Lifevantage CorporationLFVN
$138.73M-0.2%

Other financials

Income statement

See full
Revenue$44.9M-8.3%
Gross profit$31.0M-14.9%
Operating income$3.2M-67.3%
Net income$2.3M-83.4%
EPS (diluted)$0.06-83.8%

Balance sheet

See full
Cash & equivalents$5.3M-87.2%
Total debt$103.4M-5.5%
Total equity-$56.1M+37.7%
Total assets$89.0M-27.8%

Cash flow

See full
Operating cash flow$3.9M-39.7%
CapEx$362.0K-77.8%
Free cash flow$3.5M-26.8%

Valuation

See full
Market cap$57.33M-51.2%
Enterprise value$155.43M-26.5%
P/E3.7×-0.1×
P/S0.3×-0.3×

Profitability

See full
Gross margin70.1%-1.2pp
Operating margin15.4%-0.1pp
Net margin8.3%-2.3pp
FCF margin15.3%-3.2pp

Returns & leverage

See full
Return on equity-21.4%
Debt / equity9.1×
Current ratio1.3×-0.1×

Where this comes from

Reported directly by Biote Corp. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Biote Corp.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biote Corp.'s additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biote Corp.'s additional paid-in capital?
Biote Corp. (BTMD) reported additional paid-in capital of $0 in Q1 2026.
What is the long-term trend for Biote Corp.'s additional paid-in capital?
Over 5 years (2020 to 2025), Biote Corp.'s additional paid-in capital has grown at a -100.0% compound annual growth rate (CAGR), from $24.14K to $0.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.